SINOVAC BIOTECH LTD (SVA)

Every figure this model derived for SVA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 48,917,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 5,971,321,000 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 7,064,498,000 AssetsCurrent 2025-12-31
current liabilities 1,540,365,000 LiabilitiesCurrent 2025-12-31
equity 4,438,943,000 StockholdersEquity 2025-12-31
interest expense 9,819,000 InterestAndDebtExpense 2025-12-31
ocf -512,184,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 386,013,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 0 AllocatedShareBasedCompensationExpense 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up SVA on one particular measure came for.

RatioValue
cash operating margin-101.73
current ratio4.62
current ratio reported4.59
deferred revenue growth-7.75
dilution pct0.0
fcf margin-145.36
growth cv2.13
interest cover-49.92
operating margin-126.97
owner earnings margin-145.36
revenue growth6.82
revenue growth per share6.82
rule of 40-120.15
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about SVA's figures. Written by the derivation as it ran, not added afterwards.